Skip to main content
. 2024 Mar 6;10:1289454. doi: 10.3389/fmed.2023.1289454

Table 2.

Comparison of cardiopulmonary exercise testing between healthy controls and hospitalized COVID-19 patients.

Control subjects (N = 141) COVID-19patients (N = 47) Effect size p
ppVO2 (%)* 95 ± 35 83 ± 15 0.38 (0.05–0.71) 0.002
ppVO2 (%)** 88 ± 18 81 ± 18 0.39 (0.05–0.72) 0.039
Peak VO2 (mL/kg/min) 25.0 ± 7 22.5 ± 6 0.37 (0.04–0.70) 0.04
OUES 2,380 ± 860 2,122 ± 611 0.32 (0.01–0.65) 0.02
VO2@AT (mL/kg/min) 14.4 ± 4.4 12.8 ± 3.1 0.39 (0.05–0.72) 0.007
Peak oxygen pulse (mL/beat) 13.8 ± 3.9 13.2 ± 3.6 0.15
Peak VO2 (l/min) 2.20 ± 0.8 2.02 ± 0.7 0.19
Peak HR (bpm) 156 ± 22 156 ± 18 0.87
Peak SBP (mmHg) 169 ± 26 164 ± 20 0.23
Peak RER 1.17 ± 0.1 1.18 ± 0.1 0.47
VE/VCO2 slope 31 ± 8 31 ± 7 0.33
Peak VE (l/min) 84 ± 27 76 ± 23 0.08
ppVE (%) 106 ± 40 93 ± 39 0.12

ppVO2, predicted-percentage peak VO2; HR, heart rate; OUES, oxygen uptake efficiency slope; VO2@AT, VO2 at anaerobic threshold; SBP, systolic blood pressure; RER, respiratory exchange ratio; VE, ventilation, ppVE predicted-percentage peak VE. *Wasserman and Hansen algorithm and **FRIEND equation. Continuous data are presented as mean ± standard deviation or median (p25–p75).